Table 2.
Clinicopathological characteristics of HER2-zero Expression Evolution.
| Characteristic | Total (n = 71) |
TNBC(n = 20) |
HR positive (n = 51) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| HER2-stable n = 49 | HER2-gain n = 22 | P | HER2-stable n = 15 | HER2-gain n = 5 | P | HER2-stable n = 34 | HER2-gain n = 17 | P | |
| Histology type | 0.009 | 0.260 | 0.051 | ||||||
| IBC-NST | 34 | 22 | 9 | 5 | 25 | 17 | |||
| Other | 15 | 0 | 6 | 0 | 9 | 0 | |||
| cT | 0.714 | 0.009 | 0.234 | ||||||
| T1-2 | 29 | 12 | 15 | 2 | 14 | 10 | |||
| T3-4 | 20 | 10 | 0 | 3 | 20 | 7 | |||
| cN | 0.406 | 0.266 | 0.135 | ||||||
| N0-1 | 23 | 8 | 10 | 5 | 13 | 3 | |||
| N2-3 | 26 | 14 | 5 | 0 | 21 | 14 | |||
| Clinical stage | 0.313 | 0.347 | 1.000 | ||||||
| II | 17 | 5 | 10 | 2 | 7 | 3 | |||
| III | 32 | 17 | 5 | 3 | 27 | 14 | |||
| HR | 0.495 | – | – | ||||||
| Positive | 34 | 17 | 0 | 0 | 34 | 17 | |||
| Negative | 15 | 5 | 15 | 5 | 0 | 0 | |||
| Ki-67 | 0.025 | – | 0.036 | ||||||
| ≤ 30 % | 8 | 9 | 0 | 0 | 8 | 9 | |||
| >30 % | 41 | 13 | 15 | 5 | 26 | 8 | |||
IBC-NST, invasive breast cancer, no special type; HR, estrogen receptor.